Clarke JT - Search Results

1

Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease.

Schiffmann R, Martin RA, Reimschisel T, Johnson K, Castaneda V, Lien YH, Pastores GM, Kampmann C, Ries M, Clarke JT. Schiffmann R, et al. Among authors: clarke jt. J Pediatr. 2010 May;156(5):832-7, 837.e1. doi: 10.1016/j.jpeds.2009.11.007. Epub 2010 Jan 25. J Pediatr. 2010. PMID: 20097359 Clinical Trial.

2

Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa.

Schiffmann R, Ries M, Blankenship D, Nicholls K, Mehta A, Clarke JT, Steiner RD, Beck M, Barshop BA, Rhead W, West M, Martin R, Amato D, Nair N, Huertas P. Schiffmann R, et al. Among authors: clarke jt. Genet Med. 2013 Dec;15(12):983-9. doi: 10.1038/gim.2013.56. Epub 2013 May 16. Genet Med. 2013. PMID: 23680766 Free article. Clinical Trial.

3

Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.

Ries M, Clarke JT, Whybra C, Timmons M, Robinson C, Schlaggar BL, Pastores G, Lien YH, Kampmann C, Brady RO, Beck M, Schiffmann R. Ries M, et al. Among authors: clarke jt. Pediatrics. 2006 Sep;118(3):924-32. doi: 10.1542/peds.2005-2895. Pediatrics. 2006. PMID: 16950982 Clinical Trial.

4

Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data.

Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G, Schiffmann R, Barbey F, Ries M, Clarke JT; Fabry Outcome Survey investigators. Mehta A, et al. Among authors: clarke jt. Lancet. 2009 Dec 12;374(9706):1986-96. doi: 10.1016/S0140-6736(09)61493-8. Lancet. 2009. PMID: 19959221

5

Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents.

Ries M, Clarke JT, Whybra C, Mehta A, Loveday KS, Brady RO, Beck M, Schiffmann R. Ries M, et al. Among authors: clarke jt. J Clin Pharmacol. 2007 Oct;47(10):1222-30. doi: 10.1177/0091270007305299. Epub 2007 Aug 13. J Clin Pharmacol. 2007. PMID: 17698592 Clinical Trial.

6

The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease.

Clarke JT, West ML, Bultas J, Schiffmann R. Clarke JT, et al. Genet Med. 2007 Aug;9(8):504-9. doi: 10.1097/GIM.0b013e318133fb1b. Genet Med. 2007. PMID: 17700388 Free article. Clinical Trial.

7

Agalsidase alfa and kidney dysfunction in Fabry disease.

West M, Nicholls K, Mehta A, Clarke JT, Steiner R, Beck M, Barshop BA, Rhead W, Mensah R, Ries M, Schiffmann R. West M, et al. Among authors: clarke jt. J Am Soc Nephrol. 2009 May;20(5):1132-9. doi: 10.1681/ASN.2008080870. Epub 2009 Apr 8. J Am Soc Nephrol. 2009. PMID: 19357250 Free PMC article.

8

Proposed high-risk screening protocol for Fabry disease in patients with renal and vascular disease.

Auray-Blais C, Millington DS, Young SP, Clarke JT, Schiffmann R. Auray-Blais C, et al. Among authors: clarke jt. J Inherit Metab Dis. 2009 Apr;32(2):303-8. doi: 10.1007/s10545-009-1055-6. Epub 2009 Jan 26. J Inherit Metab Dis. 2009. PMID: 19169844

9

Enzyme replacement therapy of Fabry disease.

Clarke JT, Iwanochko RM. Clarke JT, et al. Mol Neurobiol. 2005 Aug;32(1):43-50. doi: 10.1385/MN:32:1:043. Mol Neurobiol. 2005. PMID: 16077182 Review.

10

The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I.

Pastores GM, Arn P, Beck M, Clarke JT, Guffon N, Kaplan P, Muenzer J, Norato DY, Shapiro E, Thomas J, Viskochil D, Wraith JE. Pastores GM, et al. Among authors: clarke jt. Mol Genet Metab. 2007 May;91(1):37-47. doi: 10.1016/j.ymgme.2007.01.011. Epub 2007 Mar 2. Mol Genet Metab. 2007. PMID: 17336562

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

311 results

Search Page